Pharming Group N.V.

Pharming Group N.V. (NASDAQ:PHAR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for PHAR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-11, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for PHAR spans 6-K, 20-F.

Recent high-impact activity:

• FDA Approves Joenja for Children 4–11 with APDS, First U.S. Pediatric Treatment (2026-09-11)
• FDA Expands Joenja Approval to Younger APDS Patients (2026-09-11)
• Pharming Launches Joenja in Japan, First Market for Pediatric APDS Patients (2026-08-13)
• Pharming Q2 Revenue Misses, Cuts 2026 Guidance by $30M; Joenja Grows 40% but RUCONEST Slides (2026-07-30)
• Pharming Cuts 2026 Revenue Guidance by $30M Despite Joenja Momentum (2026-07-30)

Insider Transactions

PHAR files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.